Delix Therapeutics' Novel Neuroplastogen Zalsupindole Shows No Cognitive Impairment in Phase 1b Depression Trial
核心洞察
Delix Therapeutics (搜索) presented Phase 1b data for zalsupindole (搜索) (DLX-001), a novel neuroplastogen for major depressive disorder (搜索), showing no evidence of psychotomimetic, hallucinatory, or dissociative effects.
The study utilized Cumulus Neuroscience (搜索)'s NeuLogiq Platform to confirm that zalsupindole (搜索) does not impact cognitive function, supporting potential at-home administration in future trials.
This differentiates zalsupindole (搜索) from other plastogens that require clinical observation during administration, potentially improving patient accessibility and treatment convenience.
Delix Therapeutics (搜索) has presented promising Phase 1b data for their novel neuroplastogen zalsupindole (搜索) (DLX-001) at the 2026 American Society of Clinical Neuropharmacology (ASCP) Conference, demonstrating no evidence of cognitive impairment or psychotomimetic effects in patients with major depressive disorder (搜索). The findings support the potential for at-home administration of this investigational therapy, marking a significant differentiation from other plastogen compounds that require clinical supervision.
Study Design and Digital Biomarker Integration
The Phase 1b study enrolled 18 adults with major depressive disorder (搜索) and employed Cumulus Neuroscience (搜索)'s NeuLogiq Platform alongside conventional trial measures. The comprehensive assessment included clinician-rated symptom scales (MADRS, HAM-D-17), pharmacokinetics, quantitative electroencephalography (qEEG), polysomnography, and safety assessments.
Repeated cognitive testing was performed using Symbol Swap, the NeuLogiq Platform's tablet-based cognitive assessment, which showed no evidence of acute or delayed cognitive impairment across both dosing schedules. Regular task performance and learning patterns were observed throughout the study. The Symbol Swap task represents a highly repeatable adaptation of the Digit Symbol Substitution Task (DSST), a well-validated measure of cognition widely used in depression (搜索), neurodegeneration, and neuropsychiatry clinical trials.
Pharmacodynamic Signal Detection
The study builds on interim results presented by Delix at ASCP in May 2025, which confirmed that the NeuLogiq Platform detected a pharmacodynamic signal consistent with previous observations in a Phase 1 healthy volunteer study. A consistent increase in slow-wave theta activity was observed using two separate methods: a traditional wet electrode 64-channel EEG acquisition system and the NeuLogiq Platform's novel 16-channel dry EEG headset.
"We are excited to present these latest data supporting ongoing development of zalsupindole (搜索), a novel neuroplastogen that holds much promise for millions of patients living with major depressive disorder (搜索) globally," said Eliseo Salinas, MD, MSc, Head of Research & Development at Delix Therapeutics (搜索). "The Cumulus NeuLoqiq Platform provided our team with critical data confirming that zalsupindole does not impact cognitive function, which directly supports at home administration in future studies."
Clinical Differentiation and Future Development
The absence of cognitive impairment represents a significant advantage for zalsupindole (搜索) compared to other plastogens that require administration under clinical observation. This safety profile supports at-home dosing in future trials, including the upcoming Delix placebo-controlled Phase 2 study.
Zalsupindole (搜索) is described as a novel neuroplastogen isotryptamine engineered to promote structural and functional neural plasticity without hallucinatory, sedative, or dissociative effects. Preclinical data have demonstrated that DLX-001 increases dendritic spine density in neurons in the prefrontal cortex (搜索) and has rapid and enduring antidepressant-like effects in animal models after a single dose.
Platform Evolution and Broader Applications
Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus, noted the evolution of their platform beyond its original focus. "Although the NeuLogiq Platform was initially purpose-built in collaboration with 10 biopharma companies to generate objective clinical quality data in Alzheimer's dementia, today 50% of our business is focused in neuropsychiatry," Murphy said. "Over time, NeuLogiq has evolved to be used across the spectrum of CNS conditions including multiple psychiatric disorders."
The NeuLogiq Platform enables study sponsors to capture large amounts of real-world clinical data repeatedly over time, across multiple behavioral and physiological domains, both in the clinic and at home. Combined with machine learning analytics, the platform aims to simplify and improve the robustness of CNS clinical trials while providing objective assessment of study inclusion and treatment outcomes.
Addressing Unmet Medical Need
Major depressive disorder (搜索) affects an estimated 6-7% of adults worldwide and is more prevalent in women than men. While antidepressant medications and psychotherapy are common treatments for MDD, some individuals may not respond well to these options, creating an unmet need for alternative or complementary treatments.
Neuroplastogens represent a novel class of potentially disease-modifying therapeutics for psychiatric and neurological conditions. These compounds promote rapid and sustained neuroplasticity (搜索) in select neural circuits, resulting in fast-acting therapeutic effects. The approach leverages compounds that are proving beneficial across a range of therapeutic areas including mood, anxiety, cognitive, and neurodegenerative disorders.